| Budget Amount *help |
¥177,710,000 (Direct Cost: ¥136,700,000、Indirect Cost: ¥41,010,000)
Fiscal Year 2018: ¥31,980,000 (Direct Cost: ¥24,600,000、Indirect Cost: ¥7,380,000)
Fiscal Year 2017: ¥31,980,000 (Direct Cost: ¥24,600,000、Indirect Cost: ¥7,380,000)
Fiscal Year 2016: ¥32,890,000 (Direct Cost: ¥25,300,000、Indirect Cost: ¥7,590,000)
Fiscal Year 2015: ¥38,350,000 (Direct Cost: ¥29,500,000、Indirect Cost: ¥8,850,000)
Fiscal Year 2014: ¥42,510,000 (Direct Cost: ¥32,700,000、Indirect Cost: ¥9,810,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we successfully concatenated the base molecules in DNA and RNA and the partial amino acid sequence of peptide and sequenced the entire genome of a virus by measuring the tunneling current flowing through a single molecule. We successfully observed the direct incorporation of our target anticancer drug into DNA and identified the individual molecules associated with the chemically modified base molecule and the amino acid, both of which are vital disease markers. A quantitative method was developed to analyze the base sequences and abundance ratios for the two types of DNA and RNA contained in the target solution. We determined the amino acid sequences and the abundance ratios for the two types of peptides under investigation.
|
